Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm Innolake Biopharma to utilize Escugen’s innovative antibody-drug conjugate (ADC) platform, EZWi-Fit, in the development of ADC products targeting specific antigens selected by Innolake.
Under the terms of the agreement, Innolake will employ EZWi-Fit to design and develop novel ADC products, handling all aspects from preclinical and clinical development to manufacturing and global commercialization. The Hangzhou-based company will compensate Escugen with an undisclosed upfront payment, milestone payments, and tiered royalties based on worldwide sales.
Innolake’s first-in-class ADC product, ILB-3103, developed using the EZWi-Fit technology platform, has completed the pharmacological validation of its preclinical candidate compound. The product targets DLL-3 and B7H3, two highly promising tumor-associated antigens, and is intended for the treatment of neuroendocrine-derived malignant tumors, particularly small cell lung cancer. Notably, ILB-3103’s targeting of B7H3, a broad-spectrum tumor antigen, suggests its potential to address a wider range of malignant tumors.- Flcube.com
